Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CLL
MCID: LKM071
MIFTS: 79

Leukemia, Chronic Lymphocytic (CLL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Chronic Lymphocytic

About this section

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic:

Name: Leukemia, Chronic Lymphocytic 56 73 37 39
Chronic Lymphocytic Leukemia 12 74 52 36 29 6 42 15 17 71
B-Cell Chronic Lymphocytic Leukemia 12 58 73
Cll 56 12 73
B-Cell Chronic Lymphoid Leukemia 12 58
Chronic Lymphatic Leukemia 12 73
Lymphoplasmacytic Leukemia 12 71
Small Lymphocytic Lymphoma 58 71
Leukemia, Lymphocytic, Chronic, B-Cell 43
B Cell Chronic Lymphocytic Leukemia 52
Chronic B-Cell Lymphocytic Leukemia 52
Leukemia, Lymphocytic, Chronic 52
Leukemia Lymphocytic Chronic 54
Leukemia, Chronic Lymphatic 56
Lymphoma Small Lymphocytic 54
Chronic Lymphoid Leukemia 73
B-Cll 58

Characteristics:

Orphanet epidemiological data:

58
b-cell chronic lymphocytic leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
associated with susceptibility loci on chromosome 11p11 (clls1, ), 13q14 (clls2, ), 9q34.1 (clls3, ), 6p25.3 (clls4, ), and 11q24.1 (clls5, )


HPO:

31
leukemia, chronic lymphocytic:
Inheritance somatic mutation autosomal dominant somatic cell mutation


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:1040
OMIM 56 151400
KEGG 36 H00005
ICD9CM 34 204.1
MeSH 43 D015451
NCIt 49 C3163
SNOMED-CT 67 51092000 92814006
ICD10 32 C91.1 C91.10
MESH via Orphanet 44 D015451
ICD10 via Orphanet 33 C91.1
UMLS via Orphanet 72 C0023434 C0855095 C1868683
Orphanet 58 ORPHA67038
MedGen 41 C0023434
SNOMED-CT via HPO 68 124975008 277473004
UMLS 71 C0023434 C0855095 C2854089
Sources

Summaries for Leukemia, Chronic Lymphocytic

About this section
MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic lymphocytic leukemia (CLL), there are too many lymphocytes, a type of white blood cell. CLL is the second most common type of leukemia in adults. It often occurs during or after middle age and is rare in children. Usually CLL does not cause any symptoms. If you have symptoms, they may include Painless swelling of the lymph nodes in the neck, underarm, stomach, or groin Fatigue Pain or a feeling of fullness below the ribs Fever and infection Weight loss Tests that examine the blood, bone marrow, and lymph nodes diagnose CLL. Your doctor may choose to just monitor you until symptoms appear or change. Treatments include radiation therapy, chemotherapy, surgery to remove the spleen, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Chronic Lymphocytic, also known as chronic lymphocytic leukemia, is related to leukemia and lymphocytic leukemia, and has symptoms including fatigue, angina pectoris and edema. An important gene associated with Leukemia, Chronic Lymphocytic is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Toll-like Receptor Signaling Pathway. The drugs Valganciclovir and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are cellular immunodeficiency and chronic lymphatic leukemia

Disease Ontology : 12 A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

NIH Rare Diseases : 52 Chronic lymphocytic leukemia (CLL) is a cancer of the lymphocytes (a type of white blood cell ). It begins in the stem cells of the bone marrow and then spreads to the blood. Over time, CLL may also spread to the lymph nodes and other organs , including the liver, spleen and lungs. Early signs and symptoms of CLL may include swollen lymph nodes, fatigue , weight loss, loss of appetite, fever, night sweats and/or frequent infections. The underlying cause of CLL is unknown. It usually occurs in people with no family history of the condition, but familial cases have been reported. Treatment options depend on many factors, including the stage of the condition, blood cell counts, and whether the CLL has recurred (come back). Treatment may not be necessary until a person develops symptoms or there is other evidence of rapid cancer progression. The chance of recovery and life expectancy vary from person to person. While most people with CLL live at least 5 to 10 years, some do not survive more than 2 to 3 years after the diagnosis.

OMIM : 56 Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al., 2012). (151400)

KEGG : 36 Chronic lymphocytic leukemia (CLL) is caused by the abnormal progressive accumulation of functionally incompetent monoclonal B-lymphocytes in blood, bone marrow, lymph nodes and spleen. It is the most common adult leukemia in Western countries, accounting for about 30% of total leukaemias. Worldwide there are approximately 180,000 new cases every year. A main focus in CLL research involved the evaluation of genetic features related to somatic gene mutation or deletions that disrupt apoptosis and enhance tumor cell proliferation. The best characterized genes are TP53 (also known as p53) and ATM, for which mutations and/or deletions have been described that predict rapid disease progression, resistance to conventional therapies and poor survival.

UniProtKB/Swiss-Prot : 73 Leukemia, chronic lymphocytic: A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Wikipedia : 74 Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many... more...

Sources

Related Diseases for Leukemia, Chronic Lymphocytic

About this section

Diseases in the Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic
Leukemia, Chronic Lymphocytic 1 Leukemia, Chronic Lymphocytic 3
Leukemia, Chronic Lymphocytic 4 Leukemia, Chronic Lymphocytic 5
Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1050)
# Related Disease Score Top Affiliating Genes
1 leukemia 35.0 TP53 PTPN11 NRAS KRAS HRAS CCND1
2 lymphocytic leukemia 33.7 TP53 PTPN11 MIR15A KRAS CCND1 BRAF
3 colorectal cancer 33.0 TP53 NRAS MIR424 MIR34A MIR29A MIR181A2
4 lung cancer 33.0 TP53 NRAS MIR424 MIR34A MIR29A MIR16-1
5 leukemia, acute myeloid 32.9 TP53 PTPN11 NRAS MIR424 MIR34A MIR29A
6 renal cell carcinoma, nonpapillary 32.9 TP53 NRAS MIR34A MIR145 MIR143 MIR106B
7 lymphoma, non-hodgkin, familial 32.9 TP53 NRAS MIR424 MIR34A MIR15A CCND1
8 prostate cancer 32.9 TP53 MIR34A MIR29A MIR16-1 MIR15A MIR145
9 gastric cancer 32.8 TP53 PTPN11 NRAS MIR34A MIR16-1 MIR145
10 myeloma, multiple 32.8 TP53 PTPN11 NRAS MIR181A2 MIR15A MIR106B
11 hepatocellular carcinoma 32.8 TP53 PTPN11 NRAS MIR34A MIR29A MIR181A2
12 melanoma 32.8 TP53 POT1 NRAS MIR34A MIR181A2 MIR15A
13 hematologic cancer 32.7 TP53 PTPN11 MIR424 MIR34A MIR29A MIR16-1
14 neuroblastoma 32.6 TP53 PTPN11 NRAS MIR34A MIR29A HRAS
15 lung cancer susceptibility 3 32.5 TP53 NRAS MIR15A MIR145 MIR143 KRAS
16 leukemia, acute lymphoblastic 32.4 PTPN11 MIR424 KRAS IKZF3 HRAS ATM
17 endometrial cancer 32.4 TP53 PTPN11 NRAS MIR34A MIR145 MIR106B
18 cervical cancer 32.4 TP53 MIR424 MIR34A MIR29A MIR15A MIR145
19 esophageal cancer 32.3 TP53 MIR424 MIR34A MIR145 MIR143 MIR107
20 diffuse large b-cell lymphoma 32.3 TP53 MIR145 MIR143 CCND1
21 glioblastoma multiforme 32.3 TP53 NRAS MIR34A KRAS HRAS CCND1
22 lymphoma 32.2 TP53 PTPN11 NRAS CCND1 BRAF ATM
23 myeloid leukemia 32.2 TP53 PTPN11 NRAS KRAS HRAS
24 leukemia, chronic myeloid 32.2 TP53 PTPN11 NRAS KRAS HRAS CCND1
25 glioma 32.2 TP53 POT1 MIR34A MIR181A2 MIR15A CCND1
26 bladder cancer 32.2 TP53 NRAS MIR34A MIR145 MIR143 MIR106B
27 squamous cell carcinoma, head and neck 32.1 TP53 MIR424 MIR16-1 MIR15A MIR145 HRAS
28 acute promyelocytic leukemia 32.1 NRAS MIR16-1 MIR15A KRAS HRAS CCND1
29 adenoma 32.1 TP53 KRAS CCND1 BRAF
30 burkitt lymphoma 32.0 TP53 MIR145 MIR143 CCND1 ATM
31 gastric adenocarcinoma 32.0 TP53 NRAS MIR16-1 MIR107 KRAS HRAS
32 sarcoma 32.0 TP53 NRAS KRAS HRAS CCND1 BRAF
33 t-cell leukemia 32.0 TP53 NRAS MIR143 KRAS HRAS CCND1
34 pancreatic adenocarcinoma 32.0 TP53 MIR145 KRAS HRAS CCND1 BRAF
35 kidney cancer 32.0 TP53 MIR424 MIR29A MIR15A MIR106B
36 cll/sll 31.9 TP53 CCND1 ATM
37 rectum cancer 31.9 MIR424 MIR29A MIR145 MIR143 KRAS HRAS
38 oral squamous cell carcinoma 31.9 TP53 MIR34A MIR29A MIR145 MIR143 MIR107
39 nervous system disease 31.9 TP53 MIR424 MIR34A MIR29A MIR15A MIR145
40 thyroid carcinoma 31.9 TP53 NRAS HRAS BRAF
41 adenocarcinoma 31.8 TP53 KRAS HRAS CCND1 BRAF
42 melanoma, cutaneous malignant 1 31.8 TP53 POT1 NRAS HRAS CCND1 BRAF
43 myelodysplastic syndrome 31.8 TP53 PTPN11 NRAS MIR34A KRAS HRAS
44 prolymphocytic leukemia 31.7 TP53 CCND1 ATM
45 neurofibromatosis, type iv, of riccardi 31.7 TP53 PTPN11 KRAS HRAS
46 skin squamous cell carcinoma 31.6 TP53 NRAS HRAS CCND1 BRAF
47 in situ carcinoma 31.6 TP53 MIR143 MIR106B HRAS CCND1
48 noonan syndrome 1 31.6 PTPN11 NRAS KRAS HRAS BRAF
49 mantle cell lymphoma 31.6 TP53 MIR16-1 CCND1 ATM
50 larynx cancer 31.6 TP53 MIR34A MIR143 MIR106B CCND1

Comorbidity relations with Leukemia, Chronic Lymphocytic via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Acute Cystitis
Agammaglobulinemia, X-Linked Anemia, Autoimmune Hemolytic
Bronchitis Chronic Leukemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Leukemia Neutropenia

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic:



Diseases related to Leukemia, Chronic Lymphocytic
Sources

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic

About this section

Human phenotypes related to Leukemia, Chronic Lymphocytic:

31
# Description HPO Frequency HPO Source Accession
1 cellular immunodeficiency 31 HP:0005374
2 chronic lymphatic leukemia 31 HP:0005550

Symptoms via clinical synopsis from OMIM:

56
Hematology:
chronic lymphatic leukemia

Laboratory Abnormalities:
recurring t(11,14) and t(14,19)(q32,q13.1) translocations

Immunology:
impaired cellular and humoral immunity

Clinical features from OMIM:

151400

UMLS symptoms related to Leukemia, Chronic Lymphocytic:


fatigue, angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ATM BRAF CCND1 HRAS KRAS NRAS

MGI Mouse Phenotypes related to Leukemia, Chronic Lymphocytic:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.7 BRAF CCND1 HRAS KRAS NRAS PTPN11
2 neoplasm MP:0002006 9.61 ATM BRAF CCND1 HRAS IKZF3 KRAS
3 pigmentation MP:0001186 9.02 BRAF KRAS NRAS PTPN11 TP53
Sources

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic

About this section

Drugs for Leukemia, Chronic Lymphocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 520)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4
Pancrelipase Approved, Investigational Phase 4 53608-75-6
5
Chlorambucil Approved Phase 4 305-03-3 2708
6 Immunologic Factors Phase 4
7 Vaccines Phase 4
8 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
9 Hydrocortisone hemisuccinate Phase 4
10 Hydrocortisone 17-butyrate 21-propionate Phase 4
11 pancreatin Phase 4
12 Hematinics Phase 4
13 Epoetin alfa Phase 4 113427-24-0
14 Orange Approved Phase 3
15
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
16
Pixantrone Approved, Investigational Phase 3 144510-96-3
17
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
18
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
19
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
20
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
21
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
22
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
23
Ondansetron Approved Phase 3 99614-02-5 4595
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Dalteparin Approved Phase 3 9005-49-6
26
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
27
Ofloxacin Approved Phase 3 82419-36-1 4583
28
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
29
Piperacillin Approved Phase 3 66258-76-2 43672
30
Tazobactam Approved Phase 3 89786-04-9 123630
31
Vancomycin Approved Phase 3 1404-90-6 441141 14969
32
Acyclovir Approved Phase 3 59277-89-3 2022
33
Ribavirin Approved Phase 3 36791-04-5 37542
34
Palivizumab Approved, Investigational Phase 3 188039-54-5
35
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
36
Captopril Approved Phase 3 62571-86-2 44093
37
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
38
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
39
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
40
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
41
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
42
ofatumumab Approved Phase 3 679818-59-8 6918251
43
Idelalisib Approved Phase 3 870281-82-6
44
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
45
Iodine Approved, Investigational Phase 3 7553-56-2 807
46
Polyestradiol phosphate Approved Phase 3 28014-46-2
47
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
48
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
49
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
50
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946

Interventional clinical trials:

(show top 50) (show all 1867)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
3 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
4 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
5 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
6 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
7 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
8 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
9 Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation Completed NCT00331162 Phase 4 Alemtuzumab;Anti-Thymocyte Globulin
10 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
11 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
12 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
13 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
14 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
15 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
16 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
17 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
18 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
19 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
20 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
21 Phase III, Controlled, Double-blind, Randomized Study of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3 Cholecalciferol;oleum neutralicum
22 A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
23 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
24 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
25 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
26 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
27 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
28 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
29 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
30 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
31 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
32 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
33 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
34 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
35 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
36 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
37 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
38 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
39 A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00086580 Phase 3
40 Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
41 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
42 Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00564512 Phase 3 cyclophosphamide;fludarabine
43 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
44 Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
45 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
46 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
47 Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide Completed NCT00004218 Phase 3 chlorambucil;cyclophosphamide;doxorubicin hydrochloride;fludarabine phosphate;prednisolone;vincristine sulfate
48 A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00718549 Phase 3 Cladribine;Cyclophosphamide;Rituximab
49 Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
50 Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Lymphocytic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Chronic Lymphocytic:
Hematopoietic stem cells for treatment of hematologic malignancies
Blood stem cell transplantation for hematological diseases
Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Lymphocytic:
Bone marrow-derived hematopoietic stem cells
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Sources

Genetic Tests for Leukemia, Chronic Lymphocytic

About this section

Genetic tests related to Leukemia, Chronic Lymphocytic:

# Genetic test Affiliating Genes
1 Chronic Lymphocytic Leukemia 29
Sources

Anatomical Context for Leukemia, Chronic Lymphocytic

About this section

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic:

40
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Lymph Node, Spleen
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Chronic Lymphocytic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease
Sources

Publications for Leukemia, Chronic Lymphocytic

About this section

Articles related to Leukemia, Chronic Lymphocytic:

(show top 50) (show all 16041)
# Title Authors PMID Year
1
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. 61 46 56
16251535 2005
2
miR-15 and miR-16 induce apoptosis by targeting BCL2. 61 46 56
16166262 2005
3
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. 54 61 56
12595313 2003
4
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. 54 61 56
12724482 2003
5
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. 61 56
23770605 2013
6
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. 61 56
22150006 2011
7
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. 61 56
22158541 2011
8
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. 61 56
21131588 2011
9
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. 54 61 46
19717645 2009
10
Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. 61 56
17047154 2007
11
HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. 61 56
15931393 2005
12
Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. 61 56
15161669 2004
13
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. 61 56
14973191 2004
14
Cytogenetic findings in familial B-cell chronic lymphocytic leukemia: a report of two cases in a family. 61 56
12781453 2003
15
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 61 56
12434020 2002
16
Hereditary chronic lymphocytic leukemia: an extended family study and literature review. 61 56
12407690 2002
17
Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. 61 56
11090088 2000
18
Genomic aberrations and survival in chronic lymphocytic leukemia. 61 56
11136261 2000
19
Anticipation in familial chronic lymphocytic leukemia. 61 56
10364544 1999
20
Anticipation in familial leukemia. 61 56
8900225 1996
21
Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. 61 56
3122218 1987
22
Human heavy-chain variable region gene family nonrandomly rearranged in familial chronic lymphocytic leukemia. 61 56
3120193 1987
23
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. 61 56
6610211 1984
24
Familial chronic lymphocytic leukemia. 61 56
6418939 1983
25
Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. 61 56
7001171 1980
26
Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. 61 56
818930 1976
27
Familial chronic lymphocytic leukemia. 61 56
4184386 1969
28
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. 61 42
31468122 2019
29
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting: commentary. 61 42
31545308 2019
30
Mutations driving CLL and their evolution in progression and relapse. 56
26466571 2015
31
Non-coding recurrent mutations in chronic lymphocytic leukaemia. 56
26200345 2015
32
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. 56
21642962 2011
33
Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. 61 46
21130495 2011
34
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. 61 46
20566844 2010
35
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. 61 46
20089965 2010
36
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. 61 46
19692702 2009
37
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. 61 46
19144983 2009
38
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. 61 46
19096009 2009
39
MiR-15a and miR-16-1 cluster functions in human leukemia. 61 46
18362358 2008
40
Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. 61 46
17989717 2008
41
The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. 61 46
17707831 2007
42
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. 61 46
17327404 2007
43
Trinucleotide repeat dynamic mutation identifying susceptibility in familial and sporadic chronic lymphocytic leukaemia. 56
17116127 2007
44
Familial cancer associated with a polymorphism in ARLTS1. 56
15843669 2005
45
Predicting Progression--ZAP-70 in CLL. 56
15329421 2004
46
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. 61 46
15284443 2004
47
MicroRNAs: genomics, biogenesis, mechanism, and function. 56
14744438 2004
48
Molecular diagnosis of the hematologic cancers. 56
12724484 2003
49
A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. 56
11943260 2002
50
Anterior chamber infiltrates associated with systemic lymphoma: report of two cases and review of the literature. 56
11825804 2002
Sources

Variations for Leukemia, Chronic Lymphocytic

About this section

ClinVar genetic disease variations for Leukemia, Chronic Lymphocytic:

6 (show top 50) (show all 104) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
2 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
3 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
4 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
5 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
6 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
7 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
8 BRAF NM_004333.6(BRAF):c.1801A>G (p.Lys601Glu)SNV Pathogenic 13966 rs121913364 7:140453134-140453134 7:140753334-140753334
9 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
10 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
11 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
12 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
13 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
14 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
15 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
16 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
17 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
18 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
19 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
20 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser)SNV Pathogenic/Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
21 TP53 NM_000546.5(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic/Likely pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
22 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
23 BRAF NM_004333.6(BRAF):c.1780G>C (p.Asp594His)SNV Pathogenic/Likely pathogenic 375947 rs397516896 7:140453155-140453155 7:140753355-140753355
24 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
25 TP53 NM_000546.5(TP53):c.824G>A (p.Cys275Tyr)SNV Pathogenic/Likely pathogenic 215997 rs863224451 17:7577114-7577114 17:7673796-7673796
26 BRAF NM_004333.6(BRAF):c.1802A>C (p.Lys601Thr)SNV Pathogenic/Likely pathogenic 44818 rs397507484 7:140453133-140453133 7:140753333-140753333
27 KRAS NM_033360.4(KRAS):c.183A>T (p.Gln61His)SNV Pathogenic/Likely pathogenic 45117 rs17851045 12:25380275-25380275 12:25227341-25227341
28 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)SNV Pathogenic/Likely pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
29 PTPN11 NM_002834.4(PTPN11):c.214G>A (p.Ala72Thr)SNV Pathogenic/Likely pathogenic 177754 rs121918453 12:112888198-112888198 12:112450394-112450394
30 HRAS NM_005343.4(HRAS):c.38G>T (p.Gly13Val)SNV Pathogenic/Likely pathogenic 180848 rs104894226 11:534285-534285 11:534285-534285
31 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val)SNV Pathogenic/Likely pathogenic 182968 rs587781525 17:7577096-7577096 17:7673778-7673778
32 FBXW7 NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys)SNV Likely pathogenic 69961 rs149680468 4:153247289-153247289 4:152326137-152326137
33 TP53 NM_000546.5(TP53):c.578A>G (p.His193Arg)SNV Likely pathogenic 184979 rs786201838 17:7578271-7578271 17:7674953-7674953
34 TP53 NM_000546.5(TP53):c.577C>T (p.His193Tyr)SNV Likely pathogenic 230256 rs876658468 17:7578272-7578272 17:7674954-7674954
35 TP53 NM_000546.5(TP53):c.743G>C (p.Arg248Pro)SNV Likely pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
36 SF3B1 NM_012433.3(SF3B1):c.1996A>G (p.Lys666Glu)SNV Likely pathogenic 376008 rs754688962 2:198267361-198267361 2:197402637-197402637
37 PLCG2 NM_002661.5(PLCG2):c.1993C>T (p.Arg665Trp)SNV Likely pathogenic 376213 rs1057519831 16:81946260-81946260 16:81912655-81912655
38 HRAS , LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu)SNV Likely pathogenic 376033 rs121913233 11:533874-533874 11:533874-533874
39 BTK NM_001287345.1(BTK):c.1039-1483T>ASNV Likely pathogenic 376204 rs1057519826 X:100611165-100611165 X:101356177-101356177
40 PLCG2 NM_002661.5(PLCG2):c.2535A>C (p.Leu845Phe)SNV Likely pathogenic 376214 rs1057519832 16:81962183-81962183 16:81928578-81928578
41 PLCG2 NM_002661.5(PLCG2):c.2535A>T (p.Leu845Phe)SNV Likely pathogenic 376215 rs1057519832 16:81962183-81962183 16:81928578-81928578
42 BRAF NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn)SNV Likely pathogenic 376286 rs121913365 7:140453132-140453132 7:140753332-140753332
43 HRAS , LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro)SNV Likely pathogenic 376322 rs121913233 11:533874-533874 11:533874-533874
44 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys)SNV Likely pathogenic 376414 rs867384286 4:153249385-153249385 4:152328233-152328233
45 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His)SNV Likely pathogenic 376415 rs1057519895 4:153249384-153249384 4:152328232-152328232
46 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro)SNV Likely pathogenic 376416 rs1057519895 4:153249384-153249384 4:152328232-152328232
47 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu)SNV Likely pathogenic 376417 rs1057519895 4:153249384-153249384 4:152328232-152328232
48 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly)SNV Likely pathogenic 376418 rs867384286 4:153249385-153249385 4:152328233-152328233
49 FBXW7 NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly)SNV Likely pathogenic 376423 rs149680468 4:153247289-153247289 4:152326137-152326137
50 FBXW7 NM_001349798.2(FBXW7):c.1514G>T (p.Arg505Leu)SNV Likely pathogenic 376424 rs1057519896 4:153247288-153247288 4:152326136-152326136

Copy number variations for Leukemia, Chronic Lymphocytic from CNVD:

7 (show top 50) (show all 1219)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14042 1 103366560 104230405 Loss Chronic lymphocytic leukemia
2 14895 1 110954839 111582296 Loss Chronic lymphocytic leukemia
3 14947 1 111421057 111642223 Loss Chronic lymphocytic leukemia
4 15456 1 115719205 117399077 Loss Chronic lymphocytic leukemia
5 17206 1 141510591 145121245 Deletion Chronic lymphocytic leukemia
6 17207 1 141510591 145121245 Loss Chronic lymphocytic leukemia
7 18527 1 146265358 148164994 Gain Chronic lymphocytic leukemia
8 19758 1 151208615 155645185 Gain Chronic lymphocytic leukemia
9 20025 1 152611898 157344161 Loss Chronic lymphocytic leukemia
10 21378 1 158336749 159355008 Loss Chronic lymphocytic leukemia
11 21384 1 158391645 159433573 Loss Chronic lymphocytic leukemia
12 21385 1 158391645 189498990 Loss Chronic lymphocytic leukemia
13 23023 1 170758115 170759115 Loss Chronic lymphocytic leukemia
14 23030 1 170822660 170823660 Gain Chronic lymphocytic leukemia
15 23626 1 172107770 172108770 Gain Chronic lymphocytic leukemia
16 24171 1 176708253 177307399 Gain Chronic lymphocytic leukemia
17 25274 1 186459864 186720923 Loss Chronic lymphocytic leukemia
18 25359 1 187890295 188217703 Loss Chronic lymphocytic leukemia
19 25435 1 189143434 189363313 Gain Chronic lymphocytic leukemia
20 25473 1 189804292 192389810 Gain Chronic lymphocytic leukemia
21 25685 1 193314169 193528753 Gain Chronic lymphocytic leukemia
22 26789 1 202768030 203457313 Loss Chronic lymphocytic leukemia
23 26818 1 203067017 205298659 Loss Chronic lymphocytic leukemia
24 26975 1 204424298 206588789 Loss Chronic lymphocytic leukemia
25 28076 1 218313329 220732423 Loss Chronic lymphocytic leukemia
26 28130 1 218942571 219164038 Loss Chronic lymphocytic leukemia
27 28133 1 218959043 244561923 Loss Chronic lymphocytic leukemia
28 28265 1 220678511 222112407 Gain Chronic lymphocytic leukemia
29 28321 1 221304071 221582122 Gain Chronic lymphocytic leukemia
30 28577 1 223594083 225234079 Loss Chronic lymphocytic leukemia
31 28643 1 224353010 225571533 Loss Chronic lymphocytic leukemia
32 28702 1 224857883 233411748 Loss Chronic lymphocytic leukemia
33 29066 1 227299711 227518155 Loss Chronic lymphocytic leukemia
34 29113 1 227696842 233631743 Loss Chronic lymphocytic leukemia
35 29265 1 229664393 229947546 Gain Chronic lymphocytic leukemia
36 29501 1 232707626 233302391 Loss Chronic lymphocytic leukemia
37 31053 1 24943712 26054939 Loss Chronic lymphocytic leukemia
38 31193 1 25985121 29490451 Deletion Chronic lymphocytic leukemia
39 31425 1 27504484 28494376 Loss Chronic lymphocytic leukemia
40 32443 1 36783544 38823237 Loss Chronic lymphocytic leukemia
41 33495 1 45606989 46307302 Gain Chronic lymphocytic leukemia
42 34016 1 51545765 53346467 Loss Chronic lymphocytic leukemia
43 34255 1 54029769 55100800 Loss Chronic lymphocytic leukemia
44 34911 1 57712092 58034742 Gain Chronic lymphocytic leukemia
45 35379 1 62697088 63142732 Loss Chronic lymphocytic leukemia
46 35406 1 63335974 63596958 Gain Chronic lymphocytic leukemia
47 35407 1 63335974 63641668 Gain Chronic lymphocytic leukemia
48 36497 1 76364563 76710672 Loss Chronic lymphocytic leukemia
49 36890 1 82341866 82576806 Loss Chronic lymphocytic leukemia
50 36895 1 82581235 82812961 Loss Chronic lymphocytic leukemia
Sources

Expression for Leukemia, Chronic Lymphocytic

About this section
Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic.
Sources

Pathways for Leukemia, Chronic Lymphocytic

About this section

Pathways related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 13.42 TP53 PTPN11 NRAS KRAS HRAS CCND1
2
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.18 TP53 NRAS KRAS HRAS CCND1 BRAF
3
PI3K-Akt signaling pathway 36
Show member pathways
 13.06 TP53 NRAS KRAS HRAS CCND1 ATM
4
Human cytomegalovirus infection 36
Show member pathways
 13.01 TP53 NRAS KRAS HRAS CCND1 ATM
5
Pathways in cancer 36
12.91 TP53 NRAS KRAS HRAS CCND1 BRAF
6
Endometrial cancer 36
Show member pathways
 12.9 TP53 PTPN11 NRAS KRAS HRAS CCND1
7
Apoptosis Modulation and Signaling 1
Show member pathways
 12.87 TP53 NRAS KRAS HRAS ATM
8
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.84 PTPN11 KRAS HRAS CCND1 BRAF
9
MAPK signaling pathway 36 1
12.83 TP53 NRAS KRAS HRAS BRAF
10
Gastric cancer 36
Show member pathways
 12.82 TP53 NRAS KRAS HRAS CCND1 BRAF
11
Ras signaling pathway 36
Show member pathways
 12.8 PTPN11 NRAS KRAS HRAS BRAF
12
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.79 TP53 PTPN11 NRAS KRAS HRAS
13
Development HGF signaling pathway 22
Show member pathways
 12.77 TP53 PTPN11 NRAS KRAS HRAS BRAF
14
4-1BB Pathway 63
Show member pathways
 12.73 TP53 NRAS KRAS HRAS BRAF
15
Immune response IL-23 signaling pathway 22
Show member pathways
 12.66 TP53 PTPN11 NRAS KRAS HRAS
16
Glioma 36
Show member pathways
 12.66 TP53 NRAS KRAS HRAS CCND1 BRAF
17
Negative regulation of FGFR3 signaling 65
Show member pathways
 12.63 PTPN11 NRAS KRAS HRAS BRAF
18
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.59 PTPN11 NRAS KRAS HRAS BRAF
19
ErbB signaling pathway 1 36
Show member pathways
 12.59 TP53 PTPN11 NRAS KRAS HRAS CCND1
20
Development ERBB-family signaling 22
Show member pathways
 12.58 TP53 NRAS KRAS HRAS BRAF
21
mTOR signaling pathway (KEGG) 64
Show member pathways
 12.57 TP53 NRAS KRAS HRAS BRAF
22
Oxytocin signaling pathway 36
Show member pathways
 12.56 NRAS KRAS HRAS CCND1 BRAF
23
Prolactin Signaling Pathway 1 36
Show member pathways
 12.55 PTPN11 NRAS KRAS HRAS CCND1
24
Apoptosis Pathway 70
Show member pathways
 12.51 TP53 NRAS KRAS HRAS ATM
25
Development FGFR signaling pathway 22
Show member pathways
 12.47 PTPN11 NRAS KRAS HRAS
26
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 12.47 PTPN11 NRAS KRAS HRAS BRAF
27
Phospholipase D signaling pathway 36
Show member pathways
 12.46 PTPN11 NRAS KRAS HRAS
28
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.46 PTPN11 KRAS HRAS BRAF
29
Development IGF-1 receptor signaling 22
Show member pathways
 12.45 TP53 PTPN11 HRAS CCND1
30
DNA Damage Response 1
Show member pathways
 12.44 TP53 MIR16-1 MIR106B CCND1 ATM
31
CNTF Signaling 63
Show member pathways
 12.4 NRAS KRAS HRAS BRAF
32
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.39 PTPN11 NRAS KRAS HRAS
33
Paradoxical activation of RAF signaling by kinase inactive BRAF 65
Show member pathways
 12.36 NRAS KRAS HRAS BRAF
34
Viral carcinogenesis 36
12.35 TP53 NRAS KRAS HRAS CCND1
35
Human T-cell leukemia virus 1 infection 36
12.35 TP53 NRAS KRAS HRAS CCND1 ATM
36
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.34 TP53 PTPN11 POT1 KRAS ATM
37
Signaling by FGFR2 65
Show member pathways
 12.33 PTPN11 NRAS KRAS HRAS BRAF
38
Axon guidance 36
12.31 PTPN11 NRAS KRAS HRAS
39
Cell surface interactions at the vascular wall 65
Show member pathways
 12.3 PTPN11 NRAS KRAS HRAS
40
C-type lectin receptor signaling pathway 36
Show member pathways
 12.29 PTPN11 NRAS KRAS HRAS
41
Long-term potentiation 36
Show member pathways
 12.26 NRAS KRAS HRAS BRAF
42
Colorectal Cancer Metastasis 63
12.26 TP53 KRAS CCND1 BRAF
43
EGF/EGFR Signaling Pathway 1
12.26 PTPN11 KRAS HRAS BRAF
44
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.25 TP53 NRAS KRAS HRAS CCND1 BRAF
45
mTOR Pathway 70
Show member pathways
 12.22 TP53 NRAS KRAS HRAS BRAF
46
Longevity regulating pathway 36
Show member pathways
 12.21 TP53 NRAS KRAS HRAS
47
Development EGFR signaling via small GTPases 22
Show member pathways
 12.21 PTPN11 NRAS KRAS HRAS
48
Integrated Breast Cancer Pathway 1
12.19